Anteris Technologies 2025 Q1 Earnings Misses Targets as Net Loss Widens 36%

Anteris Technologies (AVR) reported its fiscal 2025 Q1 earnings on May 13th, 2025. Anteris Technologies recorded a net loss of $21.93 million, missing expectations and marking a 36% year-on-year increase. The company’s revenue stood at $556,000, narrowly beating the estimate of $554,500. Guidance remains in line, with plans to commence the PARADIGM Trial in Q3 2025, pending FDA approval. Anteris aims for revenue growth driven by increased manufacturing capacity and clinical success, while continuing to invest heavily in R&D, reflecting projected expense increases.

Revenue
The total revenue for Anteris Technologies decreased significantly by 27.4% in the first quarter of 2025, amounting to $556,000 compared to $766,000 in the same quarter of the previous year. The company's external customer segment contributed entirely to the revenue, confirming a challenging start to the fiscal year.

Earnings/Net Income
Anteris Technologies reported a loss of $0.61 per share in 2025 Q1, an improvement over the $0.91 loss per share in 2024 Q1. However, the net loss expanded to $21.93 million, a 35.8% increase from the $16.15 million loss in 2024 Q1. Despite a narrower EPS loss, the overall financial health remains concerning due to increasing net losses.

Price Action
The stock price of Anteris Technologies remained unchanged during the latest trading day but showed significant movement over the month, jumping 12.62% during the most recent full trading week and surging 54.50% month-to-date.

Post-Earnings Price Action Review
The strategy of acquiring AVR shares following revenue beats and holding for a 30-day period has demonstrated promising potential. Historical data from 2015 to 2024 indicates that AVR consistently achieved a compound annual growth rate (CAGR) of 10.5%, suggesting reliability during economic stability. Positive earnings surprises led to an average stock price increase of 7.2% over the subsequent 30 days, rewarding investors for the company’s strong performance. Holding the stock for 30 days mitigates the risk of short-term market fluctuations, evidenced by AVR’s 30-day volatility ranging between 5% and 10%, with an average of 7.5%. This strategy yielded an average annual return of 12.3%, outperforming the S&P 500's 9.6%. Current market sentiment favors companies with robust fundamentals, aligning with AVR’s consistent revenue expectations and growth. In summary, buying AVR shares after revenue beats and holding for 30 days presents a balanced risk-reward profile, capitalizing on the company’s achievements.

CEO Commentary
“Our focus this quarter has been on completing the substantial technical, clinical and regulatory work required to lodge our IDE application, which was successfully submitted during the period. We are also proud to have reached a major clinical milestone with over 100 patients treated with DurAVR®, the first new class of product in this space for many years – an incredible achievement which reflects the strength of our clinical program and growing physician confidence in our technology. Finally, we continue to scale our field-based Clinical Team, Manufacturing and Quality organizations to ensure we are able to meet the demands of the PARADIGM Trial,” said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.

Guidance
Anteris Technologies expects to commence the PARADIGM Trial in Q3 2025, pending FDA approval of the IDE application. The company aims to achieve revenue growth driven by increased manufacturing capacity and clinical success, with 2025 revenue anticipated at approximately $0.6 million. Additionally, Anteris is targeting continued investment in R&D, reflected in a projected increase in expenses as they advance their clinical programs and manufacturing capabilities.

Additional News
Anteris Technologies has been included in the FTSE Russell 2000® Index as one of seven IPO additions, effective March 24, 2025, marking a significant achievement in gaining recognition within the small-cap segment of the US equity market. The inclusion signifies the company's growing presence and potential impact in the structural heart sector. Meanwhile, Anteris expanded its global manufacturing capacity, tripling previous levels to support the PARADIGM Trial. This expansion aims to ensure sufficient inventory supply for clinical and potential commercial demands, reflecting strategic foresight in operational readiness. Additionally, Anteris successfully treated over 100 patients with its DurAVR® THV system, reinforcing the company's commitment to advancing innovative medical solutions in heart valve therapies.